Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
The phase III study CheckMate 238 demonstrated improved relapse-free survival (RFS) with NIVO 3 mg/kg vs IPI 10 mg/kg in patients (pts) with resected stage III/IV melanoma. Sustained efficacy benefit at 24 mo of follow-up with NIVO vs IPI was previously reported. Here we present a 36mo analysis of efficacy and biomarker data from this study. Pts aged ≥ 15 y with completely resected stage IIIB/C or IV melanoma were randomized 1:1 to receive NIVO (3 mg/kg Q2W; N = 453) or IPI (10 mg/kg Q3W for 4 doses; Q12W thereafter; N = 453) for ≤ 1 y or until disease recurrence/unacceptable toxicity. RFS was the primary endpoint; exploratory endpoints included distant metastases-free survival (DMFS) in pts with stage III disease and potential biomarkers of efficacy. With 36 mo of follow-up, NIVO continued to demonstrate superior RFS vs IPI (HR, 0.68; P < 0.0001; 3-y RFS rates, 58% vs 45% and 188/453 vs 239/453 pts with events, respectively). Prespecified subgroup analyses demonstrated a consistent pattern similar to that of the 24-mo analysis, with HRs favoring NIVO (Table). DMFS analysis also continued to favor NIVO (Table). High levels of all biomarkers analyzed (interferon-gamma gene expression signature, tumor mutational burden, and CD8+ T-cell infiltration by immunohistochemistry) showed an association with improved RFS for both NIVO and IPI. Median RFS (mo; 24-mo follow-up) by high vs low values for each biomarker for NIVO was 30.8 vs 24.1, not reached (NR) vs 30.8, and 30.8 vs 24.9, respectively; and for IPI was NR vs 15.9, NR vs 18.3, and NR vs 13.8, respectively. With 36 mo of follow-up, NIVO continued to demonstrate superior efficacy over IPI in pts with stage III/IV melanoma at high risk of recurrence across pt subgroups. Additional analyses using composite scoring of biomarker combinations will be presented. 1310O Stratified results for ITT population, unstratified results for subgroups. Per American Joint Committee on Cancer 7th edition. Includes pts with PD-L1 status categorized as indeterminate. 1310O Stratified results for ITT population, unstratified results for subgroups. Per American Joint Committee on Cancer 7th edition. Includes pts with PD-L1 status categorized as indeterminate. NCT02388906. Wendy Sacks, PhD, and Cara Hunsberger, MS, of StemScientific, an Ashfield company, funded by Bristol-Myers Squibb. Bristol-Myers Squibb. Bristol-Myers Squibb. J.S. Weber: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celldex; Honoraria (self), Advisory / Consultancy: Ichor Medical Systems; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: cCam Biotherapeutics; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Lion Biotechnologies; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pieris Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Shareholder / Stockholder / Stock options: Altor BioScience; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: GSK; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy, Shareholder / Stockholder / Stock options: CytomX Therapeutics; Honoraria (self), Advisory / Consultancy: Nektar; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy: Medivation; Honoraria (self), Advisory / Consultancy: Sellas Life Sciences; Honoraria (self), Advisory / Consultancy: WindMIL; Non-remunerated activity/ies, named on a patent for an ipilimumab biomarker: Moffitt Cancer Center; Non-remunerated activity/ies, named on a patent for a PD-1 antibody biomarker: Biodesix; Shareholder / Stockholder / Stock options: Biond; Honoraria (self): AbbVie; Research grant / Funding (institution): InCyte; Research grant / Funding (institution): Astellas Pharma. M. Del Vecchio: Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Pierre Fabre. M. Mandala: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Honoraria (self), Advisory / Consultancy: MSD Oncology. H. Gogas: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): MSD Oncology; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: Pierre Fabre. A.M. Arance: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Speaker...